Everyone agreed the flares tracked her cycle. Nobody treated the cycle as the driver.
Where she started
Three years of HS, beginning in her early twenties, worsening steadily. Recurrent painful nodules in the underarms and groin. Intermittent discharge. Tenderness that made walking and arm movement uncomfortable. Early scarring. Bloating and an irregular appetite. Sleep disrupted during active lesions.
And a flare pattern that everybody had noticed and nobody had acted on: her lesions arrived with stress, and they arrived with her period.
This is the single most common under-treated pattern in HS, and it is most common in exactly her demographic — young women, in the years when the disease typically begins.
Why the cycle link gets noticed and not treated
The premenstrual flare is so well recognised that patients are routinely told it is expected. Some are offered an oral contraceptive or an anti-androgen, and some of those get partial relief.
But consider what that does. A hormonal medication addresses the hormonal symptom without correcting the relationship generating it — specifically, the loop between the gut and hormonal regulation. Insulin resistance raises free androgens. Androgens act on apocrine-bearing follicles. A compromised gut barrier drives the inflammatory background that all of this plays out against, and it also participates directly in hormone metabolism.
So the medication suppresses one arm of a loop it does not touch. Which is why, when it stops, the symptoms come back — and why she had been told she would need to stay on it indefinitely.
At EPOH-DSS Stage 2, with three years of disease and no established tunnelling, she was in the group that responds most completely. She was also 25, and being told to plan for a lifetime of suppression.
What treatment actually was
Phase L — oral formulations lowering the accumulated inflammatory load. Her bloating and appetite settled here.
Phase I — the phase her case turned on. Gut barrier restoration and microbiome repair, with hormonal recalibration as a core objective of the same phase, not as a separate treatment bolted on afterwards. The gut–hormone relationship is bidirectional; addressing them together is the entire point.
Phase F — internal clearance, sequenced third.
Phase E — topical formulations for lesion resolution and to prevent early scarring from consolidating.
Phase S — tapering and monitoring, with attention to the high-risk windows in her cycle.
The stress driver was addressed as a driver, not as advice. Being told "reduce your stress" when you are 25, in pain, leaking through your shirt, and afraid to raise your arm is not treatment. What changes the loop is correcting the gut and immune signalling so that the same stressor produces a smaller inflammatory response — which is what Recovery Stage 3 describes.
How it unfolded
Digestion and sleep first. Then, over the following months, the thing she had come for: the premenstrual flare stopped being inevitable. Not immediately, and not completely at first — it became smaller, then shorter, then unreliable, then absent.
Flares became less frequent and resolved more completely between episodes. Existing lesions healed without rupture. The early scarring softened rather than thickening, which at her stage was the most valuable outcome of all — because scarring that never consolidates is scarring that never becomes a sinus tract.
Why this one matters
She presented early, at a low EPOH-DSS stage, with a clearly identifiable dominant driver. That is the profile that responds most completely, and it is exactly the profile that most often gets nothing but antibiotics and a contraceptive, for years, while the disease progresses.
If your flares track your cycle, that is not a curiosity to mention in passing. It is the most useful clinical information you have, and it points directly at what should be treated.
